Schonfeld Strategic Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-20,042	Closed	-$86.6K	–	2654
2024 Q1	$86.6K	Sell	20,042 -320,742	-94%	-$1.12M	﹤0.01%	1864
2023 Q4	$1.04M	Buy	+340,784	New	+$640K	0.01%	1022
2023 Q3	–	Sell	-17,400	Closed	-$43.3K	–	2428
2023 Q2	$43.3K	Buy	+17,400	New	+$47.5K	﹤0.01%	1827
2022 Q4	–	Sell	-91,523	Closed	-$1.14M	–	3112
2022 Q3	$1.14M	Buy	+91,523	New	+$1.05M	0.01%	1179
2021 Q2	–	Sell	-14,302	Closed	-$344K	–	2395
2021 Q1	$344K	Buy	+14,302	New	+$332K	﹤0.01%	1282
2018 Q4	–	Sell	-8,205	Closed	-$429K	–	1262
2018 Q3	$429K	Buy	+8,205	New	+$447K	0.02%	606
2018 Q2	–	Sell	-11,919	Closed	-$442K	–	1016
2018 Q1	$442K	Buy	+11,919	New	+$318K	0.03%	504

Other funds holding GTHX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Schonfeld Strategic Advisors's GTHX Position: Q2 2024 in Review

Schonfeld Strategic Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 20,042 shares — an estimated $86.6K sold.

Schonfeld Strategic Advisors first reported a position in GTHX in Q1 2018 and held it in 7 quarters. The position peaked at $1.14M in Q3 2022. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

Schonfeld Strategic Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Schonfeld Strategic Advisors sold 20,042 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $86.6K.
Schonfeld Strategic Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 7 quarters.
Schonfeld Strategic Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $1.14M in Q3 2022.
88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.